Silvant Capital Management LLC Buys 2,739 Shares of Eli Lilly and Company $LLY

Silvant Capital Management LLC increased its position in Eli Lilly and Company (NYSE:LLY) by 2.4% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 115,077 shares of the company’s stock after purchasing an additional 2,739 shares during the period. Eli Lilly and Company accounts for about 4.0% of Silvant Capital Management LLC’s holdings, making the stock its 5th biggest holding. Silvant Capital Management LLC’s holdings in Eli Lilly and Company were worth $138,028,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of LLY. Willner & Heller LLC increased its holdings in shares of Eli Lilly and Company by 1.0% in the second quarter. Willner & Heller LLC now owns 917 shares of the company’s stock valued at $1,100,000 after purchasing an additional 9 shares during the period. Aspiring Ventures LLC lifted its stake in shares of Eli Lilly and Company by 3.7% in the second quarter. Aspiring Ventures LLC now owns 255 shares of the company’s stock valued at $306,000 after purchasing an additional 9 shares during the period. Wealthspan Partners LLC boosted its stake in shares of Eli Lilly and Company by 0.4% during the 2nd quarter. Wealthspan Partners LLC now owns 2,120 shares of the company’s stock worth $2,543,000 after acquiring an additional 9 shares in the last quarter. Navigoe LLC grew its holdings in Eli Lilly and Company by 8.7% in the second quarter. Navigoe LLC now owns 113 shares of the company’s stock valued at $135,000 after purchasing an additional 9 shares during the last quarter. Finally, Citizens National Bank Trust Department grew its stake in Eli Lilly and Company by 0.6% in the 4th quarter. Citizens National Bank Trust Department now owns 1,716 shares of the company’s stock valued at $1,844,000 after acquiring an additional 10 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 3.4%

NYSE:LLY opened at $1,191.49 on Thursday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The company has a market capitalization of $1.12 trillion, a price-to-earnings ratio of 39.98, a price-to-earnings-growth ratio of 1.46 and a beta of 0.51. Eli Lilly and Company has a one year low of $712.05 and a one year high of $1,292.65. The stock has a 50-day simple moving average of $1,186.29 and a 200 day simple moving average of $1,063.74.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter last year, the business posted $6.31 EPS. Eli Lilly and Company’s quarterly revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts predict that Eli Lilly and Company will post 36.35 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is 23.22%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on LLY shares. JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Tuesday, July 7th. BMO Capital Markets reiterated an “outperform” rating and issued a $1,400.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 6th. Morgan Stanley reiterated an “overweight” rating and set a $1,419.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 6th. Bank of America increased their price target on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a report on Friday, July 10th. Finally, Citigroup boosted their target price on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $1,292.18.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares of the company’s stock, valued at $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is currently owned by insiders.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA approved a blood test developed by Lilly and Roche to help identify Alzheimer’s disease. The simpler diagnostic could expand access to testing and support demand for Lilly’s Alzheimer’s drug Kisunla. Eli Lilly Clears Big Hurdle in Alzheimer’s Fight
• Positive Sentiment: A real-world study found that adults over 55 who continued using Zepbound had fewer hospital admissions and emergency-room visits, reducing healthcare costs relative to similar untreated patients. The findings could strengthen the case for Medicare and other payer coverage of the obesity drug. Zepbound linked to lower healthcare costs
• Positive Sentiment: Lilly is expanding its Alzheimer’s pipeline with new early-stage Phase 1 studies, providing additional potential beyond Kisunla. Lilly Expands Alzheimer’s Pipeline
• Neutral Sentiment: Recent institutional activity was mixed, with major investors both adding to and reducing LLY positions. Analysts’ median price target of approximately $1,348 remains above the recent trading level, but valuation and elevated expectations may limit near-term upside.
• Negative Sentiment: Renewed concern over reimbursement is weighing on sentiment. Some employers are becoming more selective about covering GLP-1 weight-loss drugs, raising questions about future Zepbound and oral obesity-drug volume growth. Companies Decline to Cover Weight-Loss Drug Costs
• Negative Sentiment: The cost-savings study may be less persuasive to payers because it measures medical savings without clearly including Zepbound’s price, leaving uncertainty about whether treatment produces net savings. Lilly’s Cost-Saving Study Leaves Out Zepbound’s Price
• Negative Sentiment: After a strong rally and a recent record high, profit-taking appears to be amplifying the reimbursement concerns. Healthcare stocks also declined late in the session. Eli Lilly Stock Pulls Back After Hitting Record Highs

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.